Ambrx Biopharma American Stock EBITDA

Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Ambrx Biopharma American Company EBITDA Analysis

Ambrx Biopharma's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

 = 

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Ambrx Biopharma EBITDA

    
  (61.75 M)  
Most of Ambrx Biopharma's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Competition

According to the company disclosure, Ambrx Biopharma American reported earnings before interest,tax, depreciation and amortization of (61.75 Million). This is 107.04% lower than that of the Biotechnology sector and 161.65% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.58% higher than that of the company.

Ambrx EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.
Ambrx Biopharma is currently under evaluation in ebitda category among its peers.

Ambrx Fundamentals

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Ambrx Stock

If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine